H3 propranolol serum levels following lidocaine administration in rats with CCL4 - induced liver damage

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 2, 2006, Pages 97-101

  Kotsiou, A ^a   Tsamouri, M ^a   Anagnostopoulou, S ^a   Tzivras, M ^a   Vairactaris, E ^a   Tesseromatis, Christine ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CCl4 liver cirrhosis; Lidocaine; Propranolol

Indexed keywords

CARBON TETRACHLORIDE; LIDOCAINE; PROPRANOLOL; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HEART; LIVER; LIVER INJURY; MALE; NONHUMAN; RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; EXPERIMENTAL LIVER CIRRHOSIS; HEART MUSCLE; METABOLISM; PATHOLOGY; WISTAR RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARBON TETRACHLORIDE; DRUG INTERACTIONS; LIDOCAINE; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MYOCARDIUM; PROPRANOLOL; RATS; RATS, WISTAR; TRITIUM;

EID: 33746685063     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191125     Document Type: Article

References (29)

1. Wilkinson GR, Schenker S. Drug disposition and liver disease. Drug Metab. Rev. 1975;4(2):139-75.
2. Wilkinson GR, Schenker S. Effects of liver disease on drug disposition in man. Biochem. Pharmacol. 1976;25(24):2675-81.
3. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin. Pharmacokinet. 1995;29(5):370-91.
4. Farrell GC, Cooksley WG, Hart P, Powell LW. Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. Gastroenterology. 1978;75(4):580-8.
5. Branch RA, Shand DG. Propranolol disposition in chronic liver disease: a physiological approach. Clin. Pharmacokinet. 1976;1(4):264-79.
6. Goto S, Yoshitomi H, Miyamoto A, Yamada H, Fujii S, Nakayama T, Fujiwara K. Further investigations on the binding of loop diuretics to serum proteins from patients with liver disease. J.Pharmacobiodyn. 1981;4(11):865-73.
7. Albengres E, Urien S, Kusmierek J, Tillement JP. Benoxaprofen: plasma binding and binding interactions with some drugs and endogenous compounds. Eur. J. Rheumatol. Inflamm. 1982;5(2):87-97.
8. Schepke M, Raab P, Hoppe A, Brensing K, Paar D, Potyka U, Sauerbruch T. Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. Alimentary Pharmacol.Ther. 1999;(13):1451.
9. Weber LW, Boll M, Stampfl A Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003;33(2):105-36.
10. Shand DG. Pharmacokinetics of propranolol: a review. Postgrad. Med. J. 1976;52Suppl 4:22-25.
11. Suzuki T, Ohkuma T, Isozaki S. Nonlinear first-pass metabolism of propranolol in the rat. J. Pharmacobiodyn. 1981;4(2):131-41.
12. Miyauchi S, Sawada Y, Iga T, Hanano M, Sugiyama Y. Dose-dependent hepatic handling of 1-propranolol determined by multiple indicator dilution method: influence of tissue binding of 1-propranolol on its hepatic elimination. Biol. Pharm. Bull. 1993;16(10):1019-24.
13. Arthur MJ, Tanner AR, Patel C, Wright R, Renwick AG, George CF. Pharmacology of propranolol in patients with cirrhosis and portal hypertension. Gut. 1985;26(1):14-9.
14. Directive 2003/15/EC of the European Parliament and of the Council of 27, February 2003: Amending Council Directive 76/768/EEC on the approximation of the laws of the Member States (text with EEA relevance).
15. Erlendsdottir H, Knudsen JD, Odenholt I, Cars O, Espersen F, Frimodt-Moller N, Fuursted K, Kristinsson KG, Gudmundsson S. Penicillin pharmacodynamics in four experimental pneumococcal infection models. Antimicrob. Agents Chemother. 2001;45(4):1078-1085.
16. Katsanos CS, Chinkes DL, Sheffield-Moore M, Aarsland A, Kobayashi H, Wolfe RR. Method for the determination of the arteriovenous muscle protein balance during non-steady-state blood and muscle amino-acid concentrations. Am. J. Physiol. Endocrinol. Metab. 2005;289(6):E1064-70. Epub 2005 Aug 9.
17. LeSage GD, Glaser SS, Marucci L, Benedetti A, Phinizy JL, Rodgers R, Caligiuri A, Papa E, Tretjak Z, Jezequel AM, Holcomb LA, Alpini G. Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver. Am. J. Physiol. 1999;276 (5 Pt 1):G1289-301.
18. Iwamoto K, Watanabe J, Araki K, Satoh M, Deguchi N. Reduced hepatic clearance of propranolol induced by chronic carbon tetrachloride treatment in rats. J. Pharmacol. Exp. Ther. 1985 Aug;234(2):470-5.
19. Belpaire FM, de Smet F, Chindavijak B, Fraeyman N, Bogaert MG. Effect of turpentine-induced inflammation on the disposition kinetics of propranolol, metoprolol, and antipyrine in the rat. Fundam. Clin. Pharmacol. 1989;3(2):79-88.
20. Rocher I, Decourt S, Leneveu A, Lebrec D, Rosier SP, Flouvat B. Hemodynamic and pharmacokinetic study of propranolol and atenolol in cirrhosis patients. Int. J. Clin. Pharmacol. Ther. Toxicol. 1985 Aug;23(8):406-10.
21. Gariepy L, Fenyves D, Villeneuve JP. Propranolol disposition in the rat: variation in hepatic extraction with unbound drug fraction. J. Pharm. Sci. 1992 Mar;81(3):255-8.
22. Nies AS, Shand DG, Wilkinson GR. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet. 1976;1(2):135-55.
23. Tesseromatis C, Fichtl B, Kurz H. Binding of non-steroid anti-inflammatory drugs and warfarin to liver tissue of rabbits in vitro. Eur. J. Drug Metab. Pharmacokinet. 1987;12(3):161-7
24. Saranteas T, Mourouzis C, Dannis C, Alexopoulos C, Lolis E, Tesseromatis C. Effect of various stress models on lidocaine pharmacokinetic properties in the mandible after masseter injection. J. Oral Maxillofac. Surg. 2004;62(7):771-2.
25. Saranteas T, Mourouzis C, Koumoura F, Tesseromatis C. Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues. J. Oral Maxillofac. Surg. 2003;61(5):604-7.
26. Saranteas T, Mourouzis C., Rallis, G., Anagnostopoulou S., Dannis K. C14-Lidocaine disposition in serum and tissues of liver diseased rats. J. Oral Maxillofac. Surg. 2006;64(6):892-5
27. Tincani E, Cioni G, D'Alimonte P, Cristani A, Turrini F, Romagnoli R, Ventura E. Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. Eur. J. Gastroenterol. Hepatol. 1995;7(9):893-7.
28. Villeneuve JP, Dagenais M, Huet PM, Lapointe R, Roy A, Marleau D. Clearance by the liver in cirrhosis. III. Propranolol uptake by the isolated perfused human liver. Can. J. Physiol. Pharmacol. 1996 Dec;74(12):1327-32.
29. Kessler KM, Humphries WC Jr, Black M, Spann JF. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. Am. Heart J. 1978;96(5):627-35.